Natalie Sicher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Natalie Sicher has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Aki Kashiwagi
Pediatric Surgical Research Laboratories, Massachusetts General Hospital
1 shared publication - Alana Mermin-Bunnell
Pediatric Surgical Research Laboratories, Massachusetts General Hospital
1 shared publication - Christina Chow
Pediatric Surgical Research Laboratories, Massachusetts General Hospital
1 shared publication - Dadi Gao
Center for Genomic Medicine and Department of Neurology, Massachusetts General Hospital, and Harvard Medical School, Boston
1 shared publication - David Pépin
Massachusetts General Hospital
1 shared publication - Eun Mi Chang
Department of Obstetrics and Gynecology, Fertility Center of CHA Gangnam Medical Center, CHA University School of Medicine, Seoul, Korea
1 shared publication
Latest Publications
- Open Access
- 28 January 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (5)
AMH protects the ovary from doxorubicin by regulating cell fate and the response to DNA damage
Anti-Müllerian hormone (AMH) protects the ovarian reserve from chemotherapy, and this effect is most pronounced with Doxorubicin (DOX). However, DOX toxicity and AMH rescue mechanisms in the ovary have remained unclear. Herein, we characterize the consequences of these treatments in ovarian cell types using scRNAseq. DOX-induced DNA damage activates Tp53 class mediators across ovarian cell types. In the mesenchyme, cotreatment with AMH halts theca progenitor differentiation and reduces apoptotic gene expression. In preantral granulosa cells, DOX upregulates the cell cycle inhibitor Cdkn1a and dysregulates Wnt signaling, which are ameliorated by AMH cotreatment. Finally, AMH induces Id3 , a gene involved in DNA repair, which is necessary to prevent the accumulation of DNA lesions marked by γ-H2AX. Altogether these mechanisms of AMH protection contribute to sustained fertility in mice, offering promising broad avenues for fertility preservation in cancer patients undergoing chemotherapy.
- 28 January 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (5)
Open AccessAMH protects the ovary from doxorubicin by regulating cell fate and the response to DNA damage
Anti-Müllerian hormone (AMH) protects the ovarian reserve from chemotherapy, and this effect is most pronounced with Doxorubicin (DOX). However, DOX toxicity and AMH rescue mechanisms in the ovary have remained unclear. Herein, we characterize the consequences of these treatments in ovarian cell types using scRNAseq. DOX-induced DNA damage activates Tp53 class mediators across ovarian cell types. In the mesenchyme, cotreatment with AMH halts theca progenitor differentiation and reduces apoptotic gene expression. In preantral granulosa cells, DOX upregulates the cell cycle inhibitor Cdkn1a and dysregulates Wnt signaling, which are ameliorated by AMH cotreatment. Finally, AMH induces Id3 , a gene involved in DNA repair, which is necessary to prevent the accumulation of DNA lesions marked by γ-H2AX. Altogether these mechanisms of AMH protection contribute to sustained fertility in mice, offering promising broad avenues for fertility preservation in cancer patients undergoing chemotherapy.